Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
04/2003
04/08/2003US6545022 Treatment of epilepsy, faintness attacks, hypokinesia, cranial disorders, neurodegenerative disorders, depression, anxiety, panic, pain, neuropathological disorders, inflammatory diseases, and gastrointestinal disorders
04/08/2003US6545018 Oxamic acids and derivatives as thyroid receptor ligands
04/08/2003US6545013 2,7-naphthyridine derivatives
04/08/2003US6545011 PARP (poly(adenosine 5'-diphospho-ribose) polymerase) inhibitors
04/08/2003US6545003 Fused ring heteroaryl and heterocyclic compounds which inhibit leukocyte adhesion mediated by VLA-4
04/08/2003US6545000 [1,2,4]triazolo[1,5-c]pyrimidine derivatives
04/08/2003US6544998 Combination of gaba agonists and sorbitol dehydrogenase inhibitors
04/08/2003US6544996 1-phenyl-4-(1-[2-aryl]cyclopropyl) methylpiperazines: dopamine receptor ligands
04/08/2003US6544995 Use of cysteine derivatives for preparing a medicine for treating pathologies resulting from the formation of heterotrimeric G protein
04/08/2003US6544993 Tetrahydrothiopyranphthalazinone derivatives as PDE4 inhibitors
04/08/2003US6544992 Carbonylamino pyrrolidine and piperidine derivatives
04/08/2003US6544987 Compounds, compositions, and methods for stimulating neuronal growth and elongation
04/08/2003US6544986 Such as 5-(N,N-dibenzyl)aminocarbonyl-2-pyridone; enzyme inhibitors; for treatment of Alzheimer's disease
04/08/2003US6544985 For therapy of acute and/or chronic neurological disorders such as psychosis, schizophrenia, Alzheimer's disease, cognitive disorders and memory deficits
04/08/2003US6544981 Anticoagulants, cardiovascular disorders
04/08/2003US6544978 Treating Alzheimer's disease both prophylactically and therapeutically
04/08/2003US6544977 Crystalline forms of 1s-[1-alpha(2s*,3r*), 9alpha]6, 10-dioxo-n-(2-ethoxy-5-oxo-tetrahydro-3-furanyl)-9[[(1-isoquinolyl)carbonyl]amino]octahydro-6h-pyridazino [1,2-a] [1,2] diazepin-1-carboxamide
04/08/2003US6544976 Treating disorders characterized by neuronal damage caused by disease or trauma, such as Parkinson's disease, Alzheimer's disease, stroke, multiple sclerosis, amyotrophic lateral sclerosis, diabetic neuropathy and Bell's palsy.
04/08/2003US6544971 Alarm device especially for detecting fires, unauthorized entry or sleep apnea, or the presence of CO, CH4, propane or radon
04/08/2003US6544960 Chemical compounds
04/08/2003US6544951 Antiinflammatory agents; autoimmune diseases, nervous system degradation
04/08/2003US6544759 Polynucleotides encoding a novel growth factor which acts through ErbB-4 kinase receptor tyrosine
04/08/2003US6544565 Administering to the host a pharmaceutically effective amount of 10(14)-Aromadendren-4-ol, 6, 10(14)- Guaiadien-4-ol, Valerenal, Valerenol, Valerenic acid, Acetoxyvalerenic acid, Hydroxyvalerenic acid or combinations thereof.
04/08/2003US6544541 Devices and compounds for treating arterial restenosis
04/08/2003US6544530 Stable oil-in-glycerin emulsion
04/08/2003US6544518 Vaccines
04/08/2003CA2252898C Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2(1h)-indol-2-one(=ziprasidone), its preparation and its use as dopamine d2 antagonist
04/08/2003CA2123548C Piperazine derivatives
04/08/2003CA2062271C Derivatives of substituted imidazol-2-one and process for their preparation
04/08/2003CA2050300C Tnf-inhibiting proteins and the preparation thereof
04/08/2003CA2049212C 6-substituted-tetrahydrobenz ¬cd| indoles
04/08/2003CA2033190C N-phenylalkyl substituted alpha-amino carboxamide derivatives and process for their preparation
04/07/2003WO2002032866A1 (4-acylaminopiperidin-1-yl) acetamides as neurokinin antagonists
04/04/2003WO2002030896A1 2,2-diphenylbutanamide derivatives and medicines containing the same
04/04/2003CA2424979A1 2,2-diphenylbutanamide derivatives and medicines containing the same
04/04/2003CA2406610A1 Embryonic stem cells and neural progenitor cells derived therefrom
04/03/2003WO2003027672A1 Novel screening method using prokineticin receptor
04/03/2003WO2003027275A1 Inhibitors of glycogen synthase kinase-3 (gsk-3) for treating glaucoma
04/03/2003WO2003027263A2 Proteins associated with cell growth, differentiation, and death
04/03/2003WO2003027254A2 15625 receptor, a novel g-protein coupled receptor
04/03/2003WO2003027234A2 Small organic molecule regulators of cell proliferation
04/03/2003WO2003027228A2 Receptors and membrane-associated proteins
04/03/2003WO2003027116A2 Substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h)one derivatives
04/03/2003WO2003027115A1 Substituted 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyrimidinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h)one derivatives for neurodegenerative disorders
04/03/2003WO2003027114A1 Preparation and use of 1,5,6,7-tetrahydropyrrolo[3,2-c]pyridine derivatives for treatment of obesity
04/03/2003WO2003027111A1 Chemical compounds
04/03/2003WO2003027102A1 3-(arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors
04/03/2003WO2003027097A1 Substituted alkylaminopyridazinone derivatives, process for the preparation thereof and pharmaceutical composition containing the same
04/03/2003WO2003027090A2 Bicyclic heterocycles as rxr ligands
04/03/2003WO2003027080A1 3-substituted-4-pyrimidone derivatives
04/03/2003WO2003027078A1 Substituted alkylaminopyridazinone derivatives, process for the preparation thereof and pharmaceutical composition containing the same
04/03/2003WO2003027076A2 1h-imidazole derivatives having cb1 agonistic, cb1 partial agonistic or cb1- antagonistic activity
04/03/2003WO2003027075A2 Substituted pyrazolyl benzenesulfamide compounds for the treatment of inflammation
04/03/2003WO2003027069A1 Preparation and use of pyrrole derivatives for treating obesity
04/03/2003WO2003027068A2 Substituted amines for the treatment of neurological disorders
04/03/2003WO2003027061A2 Muscarinic agonists
04/03/2003WO2003026743A2 Opioid formulations having reduced potential for abuse
04/03/2003WO2003026700A2 Compositions for transporting antibodies through the blood brain barrier and their use for diagnosing or treating central nervous system diseases
04/03/2003WO2003026684A1 Modulation of physiological processes and agents useful for same
04/03/2003WO2003026676A1 Anticonvulsant derivatives useful for the treatment of restless limb syndrome and periodic limb movement disorder
04/03/2003WO2003026663A1 Process for making substituted pyrazoles
04/03/2003WO2003026660A1 An enantiomerically pure diarylmethylpiperazine and methods of using same
04/03/2003WO2003026659A1 Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
04/03/2003WO2003026656A1 New formulations and use thereof
04/03/2003WO2003026655A1 New formulations and use thereof
04/03/2003WO2003026654A1 Nicotine-containing film preparation
04/03/2003WO2003026648A1 4,5-dihydro-1h-pyrazole derivatives having potent cb1-antagonistic activity
04/03/2003WO2003026647A1 Novel 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity
04/03/2003WO2003026638A1 Neuroprotective treatment methods using selective inos inhibitors
04/03/2003WO2003026634A1 Amines with antialcoholic agents
04/03/2003WO2003026622A1 Lisinopril compositions having large-particle dcpd
04/03/2003WO2003026621A2 Method for making an oral pharmaceutical product with tell-tale agents, in particular of taste and resulting product
04/03/2003WO2003026579A2 Combination therapies for immune mediated diseases
04/03/2003WO2003026566A2 Atlastin
04/03/2003WO2003026564A2 Pharmaceutical compositions for the treatment of urinary disorders
04/03/2003WO2003026563A2 Conjugated anti-psychotic drugs and uses thereof
04/03/2003WO2003026558A2 Methods and apparatuses for assuring quality and safety of drug administration and medical products and kits
04/03/2003WO2003026479A2 Methods of suppressing microglial activation
04/03/2003WO2003026408A1 Model animal with overexpression of regucalcin
04/03/2003WO2003002531A3 Fluoropyrrolidines as dipeptidyl peptidase inhibitors
04/03/2003WO2003002530A3 Pyrrolidines as dipeptidyl peptidase inhibitors
04/03/2003WO2003000269A3 Novel use for pde 10a inhibitors
04/03/2003WO2002102313A3 Pyrimidine inhibitors of phosphodiesterase (pde) 7
04/03/2003WO2002100332A3 Isoxazoline compounds having mif antagonist activity
04/03/2003WO2002089736A3 Adenosine a1 receptor antagonists for treating hypoxia-induced learning and memory impairment
04/03/2003WO2002089729A3 Fused heterocyclic compounds
04/03/2003WO2002074230A3 A dna molecule encoding a variant paraoxonase and uses thereof
04/03/2003WO2002070559A3 Nuclear hormone receptor ligand binding domains
04/03/2003WO2002062327B1 Method of treating neurological disorders using acetone derivatives
04/03/2003WO2002059256A3 Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines
04/03/2003WO2002057413A3 Peptides for activation and inhibition of delta pkc
04/03/2003WO2002045713A3 Orally-bioavailable formulations of fentanyl and congeners thereof
04/03/2003WO2002043731B1 Treatments for neurogenetic disorders, impulse control disorders, and wound healing
04/03/2003WO2002024909A9 Receptor nucleic acids and polypeptides
04/03/2003WO2002022166A9 Tweak receptor agonists as anti-angiogenic agents
04/03/2003WO2002014369A9 Human kininogen d5 domain polypeptides and their use
04/03/2003WO2002011703A9 Hybrid neuroprosthesis for the treatment of brain disorders
04/03/2003WO2002010357A3 Gsk3 polypeptides
04/03/2003WO2002010214A3 Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
04/03/2003WO2002007743A3 Piper methysticum plant extract
1 ... 1230 1231 1232 1233 1234 1235 1236 1237 1238 1239 1240 1241 1242 1243 1244 1245 1246 1247 1248 1249 1250 ... 1833